HIV vaccine trials

Finding a safe, effective HIV vaccine is crucial to stopping the pandemic. We are working with international partners on several clinical trials and capacity building projects to work towards developing an HIV vaccine.

UK HIV Vaccines Consortium (UK HVC)

The overarching aim of the UKHVC is to determine the most immunogenic vaccine strategy for HIV, i.e. to find a vaccine that provokes the best immune response against HIV, amongst combinations of existing candidates. The consortium is an integrated and project-managed collaboration of UK academic groups whose mission is to generate a series of candidate vaccines containing similar HIV antigens, so that they can be directly compared, using short, small scale clinical trials in healthy volunteers. The UK HIV Vaccine Consortium is a Wellcome Trust Strategic Award, which commenced in April 2008 and will run for five years.

UK HVC is currently supporting 3 clinical trials aiming to determine a series of viable candiate HIV vaccines.

African-European HIV Vaccine Development Network (AfrEVacc)

AfrEVacc is a network of institutional partners from Europe and Africa devoted to HIV vaccine development and building HIV vaccine trial capacity in South Africa, Tanzania & Mozambique. The project is a multi-centre international three-year project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP).

The International clinical trials research management office is providing overall project support to AfrEVacc.